Development of NEO-811, a Molecular Glue Degrader of ARNT (HIF-1β) with Potent Single Agent Activity in ccRCC

2:40 pm - Tuesday 27th October 2026

  • Targeting an “undruggable” node
  • Discovery and mechanism
  • Preclinical efficacy and clinical progress

Speakers:

Phil Chamberlain
Co-Founder, President & Chief Executive Officer
Neomorph